Summaries like this, in your inbox every morning.
Sign up free →What happened
Thermo Fisher announced new investments across three areas at BIO International 2026. On manufacturing, the company is expanding sterile fill-finish and device assembly capacity (including a collaboration with SHL Medical at its Ridgefield, New Jersey site), launching new GMP monoclonal antibody manufacturing capabilities in Plainville, Massachusetts in the second half of 2026, and adding biologics drug substance capacity in the U.S. and Switzerland. On research, Thermo Fisher is introducing AI-enabled analytics and clinical research capabilities through Clario and forming strategic partnerships with NVIDIA, OpenAI, TetraScience, and BenchSci to help customers automate laboratory workflows and unify scientific data.
Why it matters
Pharma and biotech companies are under pressure to reduce development timelines and are increasingly seeking data-driven, connected approaches across research, clinical testing, and manufacturing. Thermo Fisher positions itself as a single integrated provider that can help customers simplify complex workflows across the entire drug development lifecycle—from discovery through commercialization.
What to watch
The company is launching new GMP monoclonal antibody manufacturing in Plainville, Massachusetts in the second half of 2026, and expanding its Bioprocess Design Center network with new facilities in the U.S. and India to provide local expertise and collaborative environments for customers scaling up manufacturing.
No comments yet. Be the first to share your thoughts!
Log in to join the discussion
Get curated AI news from 200+ sources delivered daily to your inbox. Free to use.
Get Started FreeFree · takes 30 seconds · unsubscribe anytime
5 minutes a day. The AI essentials.
200+ sources · Email / LINE / Slack
